Two recent events have served to highlight the range of difficult questions raised by pharmaceuticals regulation. Last week, a man died in the French city of Rennes after a clinical trial of a painkiller went tragically wrong. In New York last month, Martin Shkreli, a former hedge fund manager, was arrested on securities fraud charges; Shkreli, who denies wrongdoing, won the sobriquet of “most hated man in America” after the company he controlled raised the price of the life-saving drug, Daraprim, from $13.50 a tablet to $750.
最近發生的兩件事突顯了藥品監管方面的多個難題。1月中旬，法國雷恩市(Rennes)一場止痛藥臨牀試驗不幸出錯，致一名男子死亡。去年12月，紐約前對沖基金經理馬丁•史克雷利(Martin Shkreli)因涉嫌證券欺詐被捕，不過他否認自己有違法行爲。先前史克雷利執掌的公司將救命藥達拉匹林(Daraprim)的售價從13.5美元一片抬高到750美元一片，令他榮獲「全美最可恨的人」封號。
您已閱讀15%（724字），剩餘85%（4155字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。